Pediatric fever treatment
This article was originally published in The Tan Sheet
Alternating acetaminophen (12.5 mg/kg) and ibuprofen (5 mg/kg) in young children is more effective for reducing fever than mono-therapy, a randomized, parallel-group trial in the February Archives of Pediatrics & Adolescent Medicine finds. The study was conducted in 464 children aged 6-36 months, with a follow-up period of 10 days. Children who received alternating doses every four hours for three days also received a lower mean number of doses per child in days 1-3, required 22.6% fewer doses from day 1-2 and had fewer fever recurrences on days five and ten, Michael Sarrell, MD, et al., Tel Aviv University, report. Difference in fever reduction between acetaminophen and ibuprofen groups was not statistically significant. Participants "may have been more seriously ill than most of the children who receive over-the-counter antipyretics" since they were recruited at presentation for treatment, the authors note...
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.